Injection of Dorsal Scapular n at Different Levels, Dose it Make Difference?

• Sponsor: Assiut University (Other)
• Overall Status: Completed
• CT.gov ID: NCT04693312
• Collaborator: (none)
• Enrollment: 60
• Location: 1
• Arms: 2
• Actual Duration (Months): 6
• Patients Per Site Per Month: 10

Study Details

Study Description

Brief Summary

Dorsal scapular nerve (DSN) entrapment syndrome is an under-recognized cause of neck and shoulder pain. DSN injuries can be the origin of a well-defined chronic pain syndrome, often referred to as DSN syndrome. DSN syndrome is often characterized by a dull ache along the medial border of the scapula.

Condition or Disease	Intervention/Treatment	Phase
Pain, Chronic	Drug: Depo medrol	Phase 2/Phase 3

Detailed Description

Dorsal scapular nerve syndrome typically presents with a weakness of the levator scapulae and the rhomboid muscles, and results in a winged scapula. A winged scapula is where the scapula protrudes from the patient's back and can affect the ability to lift objects or pull and push. The winging of the scapula seen with dorsal scapular nerve syndrome is not as severe as seen as injury or paralysis of the serratus anterior muscle.

Dorsal scapular nerve entrapment is a very under-recognized cause of neck and shoulder pain. The scapular winging may be subtle, and the symptoms are easily mistaken for other problems. A careful history and physical exam, along with a high index of suspicion, are necessary for accurate diagnosis and therefore appropriate treatment. Injection of the dorsal scapular nerve under ultrasound guidance can be diagnostic as well as therapeutic.

Study Design

• Study Type: Interventional
• Actual Enrollment: 60 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Triple (Participant, Care Provider, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: Injection of Dorsal Scapular n at Different Levels, Dose it Make Difference?
• Actual Study Start Date: Jan 1, 2020
• Actual Primary Completion Date: Mar 1, 2020
• Actual Study Completion Date: Jul 1, 2020

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Group I scalene muscle level injection of depomedrol	Drug: Depo medrol; local injection
Experimental: Group II Rheumboid muscle level injection of depomedrol	Drug: Depo medrol; local injection

Outcome Measures

Primary Outcome Measures

1. scapular pain [3 months]

   visual analog scale 1-10

Secondary Outcome Measures

1. movement pain [3 months]

   visual analog scale 1-10

2. fatigue [3 months]

   disability fatigue score

Eligibility Criteria

Criteria

• Ages Eligible for Study: 20 Years to 60 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• scapular pain

Exclusion Criteria:

• cervical radiculopathy

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Assiut governorate	Assiut		Egypt

Sponsors and Collaborators

• Assiut University

Investigators

• Principal Investigator: Manal Hassanien, MD, assistant professor

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Manal Hassanien, Assistant professor, Assiut University
• ClinicalTrials.gov Identifier: NCT04693312
• Other Study ID Numbers: Dorsal scapular entrapment
• First Posted: Jan 5, 2021
• Last Update Posted: Jan 5, 2021
• Last Verified: Dec 1, 2020

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: Chronic Pain; Methylprednisolone; Methylprednisolone Acetate; Methylprednisolone Hemisuccinate; Prednisolone; Prednisolone acetate; Prednisolone hemisuccinate; Prednisolone phosphate

Study Results

No Results Posted as of Jan 5, 2021